BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Sorafenib Dose Escalation in Renal Cell Carcinoma
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00618982
Aprotinin US Special Access Protocol
- Conditions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Registration Number
- NCT00611845
Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 69
- Registration Number
- NCT00610194
- Locations
- πΊπΈ
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
πΊπΈRoswell Park Cancer, Buffalo, New York, United States
πΊπΈUCHSC, Aurora, Colorado, United States
Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT00606125
BAY14-2222 Continuous Infusion in Surgeries
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT00606060
Long-term Extension From RCC Phase II (11515)
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 95
- Registration Number
- NCT00586495
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT00586105
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT00586521
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8101
- Registration Number
- NCT00571649
- Locations
- π¦π·
Sanatorio Mitre, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
π¨π¦CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
π¨π¦Hotel Dieu-Grace Hospital, Windsor, Ontario, Canada
SH T00186 in the Treatment of Primary Dysmenorrhea
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 223
- Registration Number
- NCT00569244
Β© Copyright 2024. All Rights Reserved by MedPath